Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Observational Non Interventional Study of Reactogenicity and Safety of the BNT162b2 Messenger Ribonucleic Acid (mRNA) Covid-19 Vaccine in Cancer Patients on Active Treatment

NCT04932863 is registered in ClinicalTrials.gov with Ente Ospedaliero Ospedali Galliera as lead sponsor.

NCT NCT04932863
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04932863 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Observational Non Interventional Study of Reactogenicity and Safety of the BNT162b2 Messenger Ribonucleic Acid (mRNA) Covid-19 Vaccine in Cancer Patients on Active Treatment
Lead sponsor
Ente Ospedaliero Ospedali Galliera
Phase
Observational
Overall status
Completed
Start date
March 15, 2021
Completion date
March 15, 2023
Enrollment
300 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, treatment-related, neoplasms